Apollomics Regains Full Compliance with Nasdaq Listing Requirements
Rhea-AI Summary
Apollomics (Nasdaq: APLM) announced that on July 8, 2026, Nasdaq Listing Qualifications Staff notified the company it has regained compliance with the Market Value of Listed Securities (MVLS) requirement under Nasdaq Listing Rule 5550(b)(2) for continued listing on the Nasdaq Capital Market.
According to Apollomics, Nasdaq previously notified the company on June 18, 2026 that it was out of compliance for failing to maintain a minimum MVLS of $35 million over 30 consecutive business days. Staff has now determined Apollomics’ MVLS was at least $35 million for 10 consecutive business days from June 23 to July 7, 2026, and the listing matter is closed.
Positive
- Regained Nasdaq MVLS compliance with ≥$35 million for 10 consecutive business days
- Nasdaq listing matter regarding Rule 5550(b)(2) is formally closed
Negative
- Received prior Nasdaq notice on June 18, 2026 for MVLS below $35 million over 30 consecutive business days
News Explained
The disclosed holder-relevant change is resolution of Apollomics’ Nasdaq market-value compliance issue, with the matter now closed.
In the
The stated test required market value of listed securities of at least
Market reaction after Nasdaq MVLS compliance update: APLM -25.01% in the Jul 13 session
In the Jul 13 session, APLM declined 25.01%, reflecting a significant negative market reaction. Argus tracked a trough of -21.4% from its starting point during tracking. Our momentum scanner triggered 20 alerts that day, indicating elevated trading interest and price volatility. Trading volume was exceptionally heavy at 8.3x the daily average, suggesting significant selling pressure.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Jun 24 | Nasdaq deficiency notice | Neutral | +7.3% | Nasdaq notice on MVLS deficiency and update on APL-101 rights in Asia. |
| Apr 27 | Full-year 2025 earnings | Neutral | -0.7% | Reported 2025 financials with new revenue, loss, and clinical development updates. |
| Apr 01 | Bridge financing | Neutral | -7.1% | Announced $2.0 million unsecured convertible note from CEO for working capital. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent APLM news often produced price moves that diverged from the apparent tone of announcements.
Key Terms
market value of listed securities financial
nasdaq capital market regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
FOSTER CITY, Calif., July 13, 2026 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and treatment-resistant cancers, today announced that on July 8, 2026, it received written notice from the Nasdaq Listing Qualifications Staff (Staff) stating that the Company regained compliance with the Market Value of Listed Securities (MVLS) requirement, as set forth in Nasdaq Listing Rule 5550(b)(2) (Rule) for continued listing on the Nasdaq Capital Market, and the matter is now closed.
As previously reported, the Company was notified by the Nasdaq Stock Market LLC on June 18, 2026, that it was not in compliance with the Rule because it failed to maintain a minimum MVLS of
About Apollomics Inc.
Apollomics Inc. is an innovative clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. Apollomics’ lead program is vebreltinib (APL-101), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors with c-Met alterations, which is currently in a Phase 2 multicohort clinical trial in the United States and other countries.
For more information, please visit www.apollomicsinc.com.
Cautionary Statement Regarding Forward-Looking Statements
This press release includes statements that constitute “forward-looking statements” within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). All statements, other than statements of present or historical fact included in this press release, regarding Apollomics’ strategy, prospects, plans, objectives and anticipated outcomes from the development and commercialization of vebreltinib are forward-looking statements. When used in this press release, the words “could,” “should,” “will,” “may,” “believe,” “anticipate,” “intend,” “estimate,” “expect,” “seek,” “project,” the negative of such terms and other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. These forward-looking statements are based on management’s current expectations and assumptions about future events and are based on currently available information as to the outcome and timing of future events. In addition, Apollomics cautions you that the forward-looking statements contained in this press release are subject to unknown risks, uncertainties and other factors, including those risks and uncertainties discussed in the Annual Report on Form 20-F for the year ended December 31, 2025, filed by Apollomics Inc. with the U.S. Securities and Exchange Commission (“SEC”) under the heading “Risk Factors” and the other documents filed, or to be filed, by Apollomics with the SEC. Additional information concerning these and other factors that may impact the operations and projections discussed herein can be found in the reports that Apollomics has filed and will file from time to time with the SEC. Forward-looking statements speak only as of the date made by Apollomics. Apollomics undertakes no obligation to update publicly any of its forward-looking statements to reflect actual results, new information or future events, changes in assumptions or changes in other factors affecting forward-looking statements, except to the extent required by applicable law.
Investor Contacts
Peter Lin, Chief Financial Officer
Apollomics, Inc.
1-650-209-4055
peter.lin@apollomicsinc.com
Peter Vozzo
ICR Healthcare
1-443-213-0505
Peter.Vozzo@icrhealthcare.com
